A naukri.com initiative
Bioengineer
1w
8
Image Credit: Bioengineer
MLN4924 Halts Renal Cancer by Stabilizing FBP1
- Researchers have discovered that MLN4924, a potent inhibitor, halts clear cell renal cell carcinoma (ccRCC) by stabilizing nuclear FBP1, a key metabolic regulator in cancer cells.
- FBP1, known for its gluconeogenic role, has shown tumor suppressor functions within the nucleus, disrupting glycolytic flux and hindering cancer cell survival pathways.
- MLN4924 inhibits the NEDD8-activating enzyme, leading to the accumulation of substrates like FBP1, thus starving cancer cells of energy sources and impeding tumor progression.
- Treatment with MLN4924 preserves nuclear FBP1 levels, inhibiting glycolysis, glutamine metabolism, and mitochondrial respiration, curbing biosynthetic pathways crucial for tumor growth.
- In animal models, MLN4924 markedly suppressed ccRCC tumor growth without significant toxicity, indicating its potential as a therapeutic option for resistant patients.
- MLN4924 blocks the proteasomal degradation of FBP1 by inhibiting cullin-RING E3 ubiquitin ligase complexes, highlighting vulnerabilities in cancer cell metabolic regulation.
- The study suggests that MLN4924 could synergize with existing therapies, disrupting ccRCC cell metabolism and potentially enhancing anti-tumor efficacy.
- Targeting the neddylation pathway with MLN4924 not only disrupts tumor metabolism but also modulates the tumor microenvironment, potentially improving patient outcomes.
- The research advocates for incorporating metabolism-targeted therapies like MLN4924 into the clinical management of ccRCC, offering a personalized and effective treatment approach.
- Stabilizing nuclear FBP1 through neddylation inhibition represents a promising strategy in overcoming metabolic diseases like ccRCC, ushering in a new era of cancer treatment.
- By understanding the interplay between MLN4924 and FBP1, this study advances the field of personalized oncology, setting the stage for innovative targeted therapeutic interventions.
Read Full Article
Like
For uninterrupted reading, download the app